Mark Sifford, MD
Pulmonary Disease · Jonesboro, ARNPI 1538155791
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,346 of the $19,977 with a category attached, or 71.8%. 60 manufacturers reported payments, led by Intuitive Surgical at 29.6% of the total. Reporting peaked in 2024 at $7,619 and has fallen 69.2% since, to $2,347 in 2025. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 771 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Jazz Pharmaceuticals Inc.$1K
- Pulmonx Corporation$686
- plus $6K from 54 others
What the payments were for
- Travel & lodging$1,2656%
- Food & beverage$14,34672%
- Education$4,19421%
- Gifts$1711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,977 in reported general payments places this provider in the 90th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 32 | $351,878 |
| GlassiaAlpha-1-Proteinase Inhibitor | 14 | $297,209 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 320 | $227,454 |
| TezspireTezepelumab-Ekko | 27 | $112,926 |
| NucalaMepolizumab | 25 | $89,224 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 115 | $85,325 |
| XolairOmalizumab | 19 | $55,078 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 35 | $21,154 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 570 | $19,770 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $18,982 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,606 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $18,404 |
| Incruse ElliptaUmeclidinium Bromide | 50 | $16,597 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $10,962 |
| Spiriva HandihalerTiotropium Bromide | 20 | $9,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat | $1,086 | $391,63793 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,619 | $370,661467 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $392 | $297,20914 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,157 | $206,401168 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $109 | $3,40227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Jonesboro
- George Williams IiJonesboro$10K
- Jeffrey CohenJonesboro$8K
- Grant CagleJonesboro$6K
- Mohammad AlnabulsiJonesboro$5K
- Joshua MorrisonJonesboro$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.